Share on StockTwits

Analysts at Canaccord Genuity hoisted their price target on shares of NxStage Medical (NASDAQ:NXTM) from $19.00 to $20.00 in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price suggests a potential upside of 42.96% from the stock’s previous close.

Shares of NxStage Medical (NASDAQ:NXTM) opened at 13.99 on Friday. NxStage Medical has a one year low of $8.77 and a one year high of $15.65. The stock’s 50-day moving average is $13.76 and its 200-day moving average is $13.28. The company’s market cap is $859.2 million.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.01. The company had revenue of $74.10 million for the quarter, compared to the consensus estimate of $70.52 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. Analysts expect that NxStage Medical will post $-0.40 EPS for the current fiscal year.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.